Physician profile
Sean Warren
NPI 1063808137
$1,646.42
in general payments reported to CMS, 2019-2025
15 companies · $284 in 2025
The $284 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $94.52 · 2021: $26.69 · 2022: $54.40 · 2023: $607 · 2024: $580 · 2025: $284.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,471.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,470.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $426.31 | 2023-2025 | Vraylar, Ubrelvy, Qulipta |
| Lilly USA, LLC | $372.10 | 2020-2024 | Mounjaro, Jardiance, Zepbound |
| Eisai INC. | $169.03 | 2025 | |
| Novo Nordisk INC | $125.90 | 2020-2025 | Ozempic, Rybelsus, Saxenda |
| Pfizer INC. | $95.46 | 2023-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $88.60 | 2023-2024 | Xifaxan, Trulance |
| Abbott Laboratories | $86.43 | 2023-2025 | Freestyle Libre 3, Freestyle Libre |
| Amgen INC. | $80.99 | 2023-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $70.68 | 2021-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.79 | 2020-2024 | Jardiance |
| Novartis Pharmaceuticals Corporation | $22.20 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.03 | 2024 | |
| Idorsia Pharmaceuticals US INC | $13.76 | 2023 | Quviviq |
| Astellas Pharma US INC | $13.27 | 2024 | Veozah |
| Biohaven Pharmaceutical Holding Company LTD. | $12.87 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sean Warren listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.